DE60123546D1 - Verwendung eines Östrogen Agonist/Antagonisten zur Verbesserung oder zur Bewahrung der urogenitalen Gesundheit - Google Patents
Verwendung eines Östrogen Agonist/Antagonisten zur Verbesserung oder zur Bewahrung der urogenitalen GesundheitInfo
- Publication number
- DE60123546D1 DE60123546D1 DE60123546T DE60123546T DE60123546D1 DE 60123546 D1 DE60123546 D1 DE 60123546D1 DE 60123546 T DE60123546 T DE 60123546T DE 60123546 T DE60123546 T DE 60123546T DE 60123546 D1 DE60123546 D1 DE 60123546D1
- Authority
- DE
- Germany
- Prior art keywords
- antagonist
- preserve
- improve
- estrogen agonist
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24078900P | 2000-10-16 | 2000-10-16 | |
US240789P | 2000-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60123546D1 true DE60123546D1 (de) | 2006-11-16 |
DE60123546T2 DE60123546T2 (de) | 2007-02-08 |
Family
ID=22907946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60123546T Expired - Lifetime DE60123546T2 (de) | 2000-10-16 | 2001-10-09 | Verwendung eines Östrogenagonisten/-antagonisten zur Verbesserung oder zur Bewahrung der urogenitalen Gesundheit |
Country Status (18)
Country | Link |
---|---|
US (4) | US20020128276A1 (de) |
EP (1) | EP1199069B1 (de) |
JP (1) | JP2002179593A (de) |
KR (1) | KR100463964B1 (de) |
AT (1) | ATE341313T1 (de) |
AU (1) | AU783821B2 (de) |
CA (1) | CA2358938C (de) |
CY (1) | CY1106263T1 (de) |
DE (1) | DE60123546T2 (de) |
DK (1) | DK1199069T3 (de) |
ES (1) | ES2272424T3 (de) |
HU (1) | HUP0104300A3 (de) |
IL (1) | IL145838A (de) |
MY (1) | MY127234A (de) |
NZ (1) | NZ514821A (de) |
PT (1) | PT1199069E (de) |
TW (1) | TWI282736B (de) |
ZA (1) | ZA200108443B (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2683853B1 (fr) * | 1991-11-14 | 1993-12-31 | Semt Pielstick | Dispositif de detection des conditions de grippage des paliers d'une machine alternative. |
WO1997012623A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
HUP0401268A2 (hu) | 2001-07-31 | 2004-11-29 | Pfizer Products Inc. | Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására |
AU2003292625B2 (en) | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
US20040248989A1 (en) * | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
EP1713770A1 (de) * | 2004-01-29 | 2006-10-25 | Eli Lilly And Company | Selektive östrogen-rezeptor-modulatoren |
US7276486B2 (en) | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
CA2573185A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
BRPI0516243C1 (pt) * | 2004-10-20 | 2021-05-25 | Endorecherche Inc | uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit |
FR2895259B1 (fr) | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
WO2007135547A2 (en) | 2006-05-22 | 2007-11-29 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
EP2034984A4 (de) | 2006-06-02 | 2013-03-06 | Pear Tree Women S Health Care | Verfahren zur behandlung atrophischer vaginitis |
US8268806B2 (en) * | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
US20110104121A1 (en) * | 2008-05-21 | 2011-05-05 | Wira Charles R | Female Reproductive Tract and Anal Prophylaxes |
PL2580210T3 (pl) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals, Inc. | Modulatory receptora estrogenowego i ich zastosowania |
EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
FI3122426T3 (fi) | 2014-03-28 | 2023-03-31 | Univ Duke | Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita |
IL310489A (en) | 2015-10-01 | 2024-03-01 | Olema Pharmaceuticals Inc | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment |
WO2017100715A1 (en) | 2015-12-09 | 2017-06-15 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulator compounds |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (de) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Mit c3-kohlenstoff verknüpfte glutarimiddegronimere zum zielproteinabbau |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3858835A1 (de) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidinbasierte antiproliferative wirkstoffe |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
AU2018291026B2 (en) | 2017-06-29 | 2022-09-01 | G1 Therapeutics, Inc. | Morphic forms of GIT38 and methods of manufacture thereof |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
CA3231270A1 (en) * | 2021-09-10 | 2023-03-16 | Ebrahim Versi | Local delivery of growth and repair promoting compounds for treating, reducing and/or preventing stress urinary incontinence and fecal incontinence |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
US5352699A (en) * | 1992-04-30 | 1994-10-04 | University Of Massachusetts Medical Center | Use of retinioc acid to treat vaginal atrophy |
US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
US5461064A (en) * | 1993-12-21 | 1995-10-24 | Eli Lilly And Company | Methods of inhibiting atrophy of the skin and vagina |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
DE19610635A1 (de) * | 1996-03-11 | 1997-09-18 | Schering Ag | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie |
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US5985910A (en) * | 1996-04-19 | 1999-11-16 | American Home Products Corporation | 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents |
US5780497A (en) * | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5935804A (en) * | 1997-03-21 | 1999-08-10 | Laine; Roger A. | Method for detecting eubacteria in biological samples with catalytically inactive murein binding enzymes |
US6027106A (en) * | 1998-11-18 | 2000-02-22 | Ernest B. Ray | Clamp apparatus |
EP1251855A1 (de) * | 2000-01-28 | 2002-10-30 | Endorecherche, Inc. | Selektive estrogenrezeptormodulatoren in kombination mit estrogenen |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
HUP0401268A2 (hu) * | 2001-07-31 | 2004-11-29 | Pfizer Products Inc. | Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására |
-
2001
- 2001-10-08 IL IL145838A patent/IL145838A/en not_active IP Right Cessation
- 2001-10-09 AT AT01308625T patent/ATE341313T1/de not_active IP Right Cessation
- 2001-10-09 ES ES01308625T patent/ES2272424T3/es not_active Expired - Lifetime
- 2001-10-09 EP EP01308625A patent/EP1199069B1/de not_active Expired - Lifetime
- 2001-10-09 DK DK01308625T patent/DK1199069T3/da active
- 2001-10-09 DE DE60123546T patent/DE60123546T2/de not_active Expired - Lifetime
- 2001-10-09 PT PT01308625T patent/PT1199069E/pt unknown
- 2001-10-11 TW TWPHARMACEUA patent/TWI282736B/zh not_active IP Right Cessation
- 2001-10-12 US US09/976,825 patent/US20020128276A1/en not_active Abandoned
- 2001-10-12 CA CA002358938A patent/CA2358938C/en not_active Expired - Fee Related
- 2001-10-12 MY MYPI20014757A patent/MY127234A/en unknown
- 2001-10-15 AU AU79412/01A patent/AU783821B2/en not_active Ceased
- 2001-10-15 JP JP2001316248A patent/JP2002179593A/ja active Pending
- 2001-10-15 NZ NZ514821A patent/NZ514821A/xx unknown
- 2001-10-15 HU HU0104300A patent/HUP0104300A3/hu unknown
- 2001-10-15 ZA ZA200108443A patent/ZA200108443B/xx unknown
- 2001-10-16 KR KR10-2001-0063744A patent/KR100463964B1/ko not_active IP Right Cessation
-
2002
- 2002-11-12 US US10/292,203 patent/US20030125319A1/en not_active Abandoned
-
2005
- 2005-05-24 US US11/137,830 patent/US20050215592A1/en not_active Abandoned
-
2006
- 2006-11-13 CY CY20061101629T patent/CY1106263T1/el unknown
-
2010
- 2010-04-22 US US12/765,298 patent/US20100204294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1199069T3 (da) | 2007-01-15 |
ATE341313T1 (de) | 2006-10-15 |
EP1199069B1 (de) | 2006-10-04 |
CA2358938A1 (en) | 2002-04-16 |
MY127234A (en) | 2006-11-30 |
US20050215592A1 (en) | 2005-09-29 |
IL145838A0 (en) | 2002-07-25 |
US20030125319A1 (en) | 2003-07-03 |
KR20020030035A (ko) | 2002-04-22 |
IL145838A (en) | 2008-11-03 |
HUP0104300A2 (en) | 2002-08-28 |
AU783821B2 (en) | 2005-12-08 |
ES2272424T3 (es) | 2007-05-01 |
HU0104300D0 (en) | 2001-12-28 |
CY1106263T1 (el) | 2011-10-12 |
PT1199069E (pt) | 2007-01-31 |
TWI282736B (en) | 2007-06-21 |
US20020128276A1 (en) | 2002-09-12 |
HUP0104300A3 (en) | 2003-05-28 |
EP1199069A2 (de) | 2002-04-24 |
NZ514821A (en) | 2004-01-30 |
KR100463964B1 (ko) | 2005-01-03 |
JP2002179593A (ja) | 2002-06-26 |
CA2358938C (en) | 2006-08-08 |
ZA200108443B (en) | 2003-04-15 |
AU7941201A (en) | 2002-04-18 |
EP1199069A3 (de) | 2003-11-19 |
DE60123546T2 (de) | 2007-02-08 |
US20100204294A1 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE341313T1 (de) | Verwendung eines östrogen agonist/antagonisten zur verbesserung oder zur bewahrung der urogenitalen gesundheit | |
ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
ATE526041T1 (de) | Verfahren zur hemmung okularer vorgänge | |
AU3084802A (en) | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
DE69829293D1 (de) | Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen | |
EP1546162A4 (de) | Auf lumineszenz basierende verfahren und sonden zur messung der cytochrom-p450-aktivitüt | |
ATE443775T1 (de) | Hif-prolylhydroxylase-aktivitätstest | |
DK1436427T3 (da) | Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons | |
ATE511655T1 (de) | Verfahren zur auswertung eines myelounterdrückungszustands | |
DE60124975D1 (de) | Automatischer apparat zum messen von wassertoxizität | |
TW200505896A (en) | Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist | |
DK1509618T3 (da) | Autoimmune sygdomme og NADPH-oxidasedefekter | |
ATE545408T1 (de) | Zusammensetzungen und verfahren zur behandlung von leukämie | |
ATE283286T1 (de) | Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion | |
DK1540338T3 (da) | Bioækvivalenstest for jernholdige formuleringer | |
BRPI0409730A (pt) | tratamento da incontinência | |
SE0401631L (sv) | Ny sammansättning | |
ATE414350T1 (de) | Cosequenz-störungsdetektion und -behandlung | |
DE60119742D1 (de) | Methode zur behandlung der hyperaktiven blase | |
NO20010509D0 (no) | Endogene konstitutivt aktiverte G-proteinkoblede orfanreseptorer | |
DK1355940T3 (da) | Urotensin II-agonister og -antagonister | |
MX2008013437A (es) | Metodo para administrar tolperisona. | |
ES2067216T3 (es) | Glutamato como factor determinante del crecimiento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |